{
    "id": 28252,
    "fullName": "EZH2 Y646F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y646F (corresponds to Y641F in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). Y646F confers a gain of function to the Ezh2 protein, as demonstrated by altered substrate specificity and increased catalytic efficiency for H3K27 trimethylation (PMID: 21190999, PMID: 24563539, PMID: 30692681).",
            "references": [
                {
                    "id": 2725,
                    "pubMedId": 24563539,
                    "title": "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24563539"
                },
                {
                    "id": 505,
                    "pubMedId": 21190999,
                    "title": "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190999"
                },
                {
                    "id": 17582,
                    "pubMedId": 30692681,
                    "title": "EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30692681"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y646F",
    "createDate": "05/13/2018",
    "updateDate": "01/21/2020",
    "referenceTranscriptCoordinates": {
        "id": 175968,
        "transcript": "NM_004456",
        "gDna": "chr7:g.148811635T>A",
        "cDna": "c.1937A>T",
        "protein": "p.Y646F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 29841,
                "profileName": "EZH2 Y646F"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2187,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tazemetostat (EPZ-6438) inhibited proliferation and promoted cell death in lymphoma cell lines harboring EZH2 Y646F in culture, and decreased tumor H3K27Me3 levels in cell line xenograft models (PMID: 24563539).",
            "molecularProfile": {
                "id": 29841,
                "profileName": "EZH2 Y646F"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2725,
                    "pubMedId": 24563539,
                    "title": "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24563539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29841,
            "profileName": "EZH2 Y646F",
            "profileTreatmentApproaches": [
                {
                    "id": 18584,
                    "name": "EZH2 inhibitor",
                    "profileName": "EZH2 Y646F"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 175968,
            "transcript": "NM_004456",
            "gDna": "chr7:g.148811635T>A",
            "cDna": "c.1937A>T",
            "protein": "p.Y646F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 175969,
            "transcript": "XM_011515884",
            "gDna": "chr7:g.148811635T>A",
            "cDna": "c.1937A>T",
            "protein": "p.Y646F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}